6-K 1 d181177d6k.htm FORM 6-K Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2016

Commission File Number: 001-36697

 

 

DBV TECHNOLOGIES S.A.

(Translation of registrant’s name into English)

 

 

177-181 avenue Pierre Brossolette

92120 Montrouge France

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x  Form 20-F            ¨  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

 

 

 

EXHIBIT LIST

 

Exhibit

   

Description

99.1    Press Release dated May 20, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    DBV TECHNOLOGIES S.A.
Date: May 20, 2016     By:  

  /s/ David Schilansky

        Name David Schilansky
        Title: Chief Operating Officer

Exhibit 99.1

 

LOGO

Press Release

Montrouge, France, May 20, 2016

DBV Technologies to Attend Upcoming

Investor Conferences

DBV Technologies, (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that members of its management team will present and host investor meetings at the following investor events:

 

  •   Susanna Mesa, Senior Vice President, Strategy, will present at the UBS Global Healthcare Conference in New York, NY, on Monday, May 23, 2016 at 3:30 pm ET

 

  •   Susanna Mesa, Senior Vice President, Strategy, will present at the Barclays West Coast Biopharma Conference in Calistoga, CA, on Wednesday, June 1, 2016 at 1:30 pm PT.

 

  •   Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Senior Vice President, Strategy, will present at the Jefferies 2016 Healthcare Conference in New York, NY, on Tuesday, June 7, 2016, at 3:30 pm ET.

A live webcast of the Jefferies 2016 Healthcare Conference will be available on the Investor Relations section of the Company’s website: http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will also be available on DBV’s website within 48 hours after the event.

About DBV Technologies

DBV Technologies developed Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

 

DBV Technologies Contact

Susanna Mesa

Senior Vice President, Strategy

+1 212-271-0861

[email protected]

 

1

LOGO

 

Media Contacts

Erinn White, Centron PR

+1 646-722-8822

[email protected]

 

Marion Janic, Rooney & Associates

+1 212-223-4017

[email protected]

 

Media Contacts, Europe

Caroline Carmagnol, Alize RP – Relation Presse

+33 (0)6 64 18 99 59

[email protected]

 

2